Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DN9V3S
|
|||
| Drug Name |
Cudetaxestat
|
|||
| Synonyms |
Cudetaxestat; BLD-0409; PAT-409; 6B7TYB2MJX; 1782070-21-6; UNII-6B7TYB2MJX; 3-((2,6-Dichloro-7-fluoro-1-(1-propyl-1H-pyrazol-4-yl)-1H-indol-3-yl)thio)-2-fluorobenzoic acid; Benzoic acid, 3-((2,6-dichloro-7-fluoro-1-(1-propyl-1H-pyrazol-4-yl)-1H-indol-3-yl)thio)-2-fluoro-; CUDETAXESTAT [INN]; CHEMBL4802146; SCHEMBL16739453; BDBM555280; GLXC-26831; EX-A6053; Cudetaxestat (Synonyms: BLD-0409); US11344533, Compound 1-13; MS-28961; HY-145561; CS-0376048; 3-{[2,6-dichloro-7-fluoro-1-(1-propylpyrazol-4-yl)indol-3-yl]sulfanyl}-2-fluorobenzoic acid; Synthesis of 3-((2,6-dichloro-7-fluoro-1-(1-propyl-1H-pyrazol-4-yl)-1H-indol-3-yl)thio)-2-fluorobenzoic acid
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Idiopathic pulmonary fibrosis [ICD-11: CB03.4; ICD-10: J84.1; ICD-9: 516.3] | Phase 2 | [1] | |
| Company |
Blade Therapeutics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H15Cl2F2N3O2S
|
|||
| Canonical SMILES |
CCCN1C=C(C=N1)N2C3=C(C=CC(=C3F)Cl)C(=C2Cl)SC4=CC=CC(=C4F)C(=O)O
|
|||
| InChI |
InChI=1S/C21H15Cl2F2N3O2S/c1-2-8-27-10-11(9-26-27)28-18-13(6-7-14(22)17(18)25)19(20(28)23)31-15-5-3-4-12(16(15)24)21(29)30/h3-7,9-10H,2,8H2,1H3,(H,29,30)
|
|||
| InChIKey |
NMDFAQXLJQRHMS-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Extracellular lysophospholipase D (E-NPP2) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Ether lipid metabolism | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05373914) RESPIRARE - A Phase 2, Randomized, Double-blinded, Placebo-controlled, Efficacy and Safety Study of Cudetaxestat (BLD-0409) Assessed Across Three Dose Ranges With or Without Standard of Care (Nintedanib or Pirfenidone) in Patients With Idiopathic Pulmonary Fibrosis (IPF). U.S.National Institutes of Health. | |||
| REF 2 | An updated patent review of autotaxin inhibitors (2017-present). Expert Opin Ther Pat. 2021 May;31(5):421-434. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.